The assay targets the binding interaction between MBNL1 and CUGexp tracts, which leads to deregulation of alternative splicing and is a key step in the pathogenesis of DM1. The assay uses a protein-RNA binding assay in 1536-well format to identify small molecule inhibitors of biotinylated (CUG)12 and his-tagged MBNL1 binding. The inhibitors of MBNL1-(CUG)12 binding disrupt time-resolved fluorescence resonance energy transfer (TR-FRET). Is the molecule effective to this assay?